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Introduction
Behçet disease (BD) is a multi-system inflammatory disorder, 
currently classified as a vasculitis. Its etiopathogenesis is unclear, 
but environmental, genetic and autoimmune factors have been 
considered.  There  have  been  ongoing  efforts  to  elucidate  the 
aetiology of BD. Many studies have investigated genetic aspects 
and immunologic features of the disorder. However, there is cer-
tainly a need for more prospective, controlled and longitudinal 
studies—not an easy endeavour considering the heterogeneity of 
BD. Immunological studies were needed particularly in inflam-
matory  sites  as  the  lung.  The  International  Study  Group  for 
Behçet Disease has established diagnostic criteria for BD, which 
make recurrent oral ulcers a mandatory finding, along with two 
of the four: recurrent genital ulcers, eye involvement, skin lesions 
and pathergy.1 While various tissue types such as blood vessel, 
eye, skin, mucosa, joint or central nervous system (CNS), may 
be affected during the course of BD, lung involvement, remains 
one of the most serious complications of the disease.2 Large vessel 
vasculitis in BD may affect the pulmonary arteries, the aorta and 
other major peripheral vessels.3-6
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BAFF has been recognized to mainly be a product of myel-
oid  cells,  such  as  monocytes,  macrophages,  dendritic  cells 
(DCs)  and  neutrophils.7,8  In  airway  inflammatory  diseases 
local B-cell class-switch recombination can mediate activa-
tion  of  airways  in  response  to  antigen  exposure.9,10  B-cell-
activating factor of the TNF family (BAFF, also known as 
BLyS, TNFSF13B, TALL-1 and THANK) is a member of the 
TNF superfamily that plays important roles in B-cell survival, 
proliferation and maturation.11 BAFF binds to 2 high-affinity 
receptors that are selectively expressed on B-cells, including 
BAFF  receptor  and  transmembrane  activator  and  CAML 
interactor (TACI). BAFF can also bind to a low-affinity recep-
tor, B-cell maturation antigen.12 Recently, it has been reported 
that BAFF is produced by bronchial epithelial cells and nasal 
epithelial cells.13
In the present study we investigated BAFF expression in the 
bronchoalveolar lavage (BAL) of active Behçet disease patients 
with  pulmonary  involvement.  We  report  also  correlations 
between BAL-BAFF levels and cell counts and that the levels 
of production were highly correlated with the appearance of 
the other B-cell-activating cytokines IL-6 and IL-13.
pulmonary artery aneurysms, arterial and venous thrombosis, pulmonary infarction, recurrent pneumonia, bronchiolitis 
obliterans organized pneumonia, and pleurisy are the main features of pulmonary involvement in Behçet disease. The 
objective of this study was to investigate the production of B-cell-activating factor of the TNF family (BAFF), an important 
regulator of B-cell survival and immunoglobulin class-switch recombination, in bronchoalveolar lavage (BAL) fluid from 
BD patients having pulmonary manifestation. Bronchoalveolar lavage (BAL) was performed in 15 BD patients with 
pulmonary manifestation and 18 BAL from healthy controls. Concentrations of B-cell-active cytokines, including BAFF, 
IL-6 and IL-13, were measured by using specific eLIsA and cytometric bead array assays. Levels of BAFF protein were 
significantly increased in BAL fluid from active BD (109 ± 21.78 pg/mL) compared with those oh healthy controls (4.83 ± 
1.75 pg/mL; p < 0.0001). In the BAL fluid, BAFF levels were significantly correlated with absolute numbers of total cells (r = 
0.823; p < 0.0001), lymphocytes (r = 0.709; p < 0.0001), neutrophils (r = 0.809; p < 0.0001) and macrophages (r = 0.742; p < 
0.0001). Normalization to albumin indicated that BAFF production occurred locally in the airways. BAFF levels were also 
significantly correlated with the other B-cell-activating cytokines IL-6 (r = 0.882, p < 0.001) and IL-13 (r = 0.659, p < 0.001).
The antigen-induced production of BAFF in the lung of active BD with pulmonary manifestations might contribute to 
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macrophages (r = 0.742, p = 0.001) (Fig. 2B) and neutrophils   
(r = 0.809, p = 0.001) (Fig. 2D).
We  also  analyzed  the  concentrations  of  the  other  B-cell-
activating cytokines IL-6 and IL-13 in the BAL fluid and in the 
serum. Confirming previous reports,15-17 we observed that the 
concentrations of IL-6 and IL-13 were significantly increased in 
serum from BD patients (Fig. 3A–C).
B-cell-activating  cytokines  in  BAL  fluid  from  active  BD 
patients were expressed at higher levels than in BAL-fluid from 
healthy controls [IL-6: 99.0 pg/ml (17.80–125.0); IL-13: 109.0 
pg/ml (37.5–159.0)] when compared to healthy-BAL fluid [IL-6: 
9.30 pg/ml (4.0–33.0); IL-13: 3.0 pg/ml (0.0–12.0)] [p < 0.0001] 
(Fig. 3A). Using BAL fluid data obtained from BD patients, we 
found that the levels of BAFF were strongly correlated with the 
levels of IL-6 (r = 0.882, p < 0.001) (Fig. 3B) and IL-13 (r = 
0.659, p < 0.0001) (Fig. 3C).
Discussion
BAFF is an important regulator of B-cell activation, proliferation 
and immunoglobulin production.8 This study provides the first 
demonstration that levels of BAFF, as well as the other B-cell-
activating cytokines IL-6 and IL-13, were significantly increased 
in BAL fluid of BD patients with pulmonary involvement. The 
concentrations of BAFF detected in BAL fluid were highly corre-
lated with the absolute numbers of recruited inflammatory cells, 
including lymphocytes, macrophages and neutrophils. The con-
centrations of antigen-induced BAFF were also correlated with 
the concentrations of the other B-cell-active cytokines IL-6 and 
IL-13. BAFF and BAFF mRNA were recently studied in BD, in 
the peripheral circulation, in skin lesion and in the central ner-
vous system.14,18
Pulmonary  aneurysms  represent  the  major  complication 
of pulmonary Behçet disease and have a poor prognosis, being 
associated with massive haemoptysis. In situ pulmonary artery 
thrombus can lead to pulmonary infarction. Superior vena cava 
thrombosis  progresses  slowly,  allowing  the  development  of  a 
prominent  collateral  circulation.  Vascular  inflammation  can 
spread to the mediastinum, the pleura and the lungs with diffuse 
pulmonary  haemorrhages,  bronchiolitis  and  organising  pneu-
monia. Electron beam tomodensitometry and MRI are the best 
diagnostic techniques for assessing pulmonary vascular lesions.3,4 
Treatment of vasculitis in BD should be based on the type of 
vascular disease and may vary among different types of vascular 
disease.
In the current study we present the first evidence that BAFF 
levels are significantly increased in BAL fluid from BD patients. 
To eliminate the possibility that the result merely reflects vascular 
leakage, we normalized values to the concentration of albumin 
as an indicator of plasma leak. Normalized BAFF concentra-
tions in BAL fluids were still significantly higher than those in 
BAL fluids of healthy controls. Serum BAFF levels were more 
increased in BD than in BAL fluid. Our results suggested that 
BAFF is produced locally in the lower airway of active BD. These 
results do not totally eliminate the possibility that vascular leak-
age or active transport contribute to the increased appearance of 
Results
Subject characteristics and inflammatory cells responses in 
BAL fluid. BAL fluids were collected from 15 subjects with BD 
and 18 healthy controls (Table 1). Recovery of BAL fluid did 
not differ between healthy controls(median, 42%; range, 16% 
to 79%) and active BD (median, 48%; range, 19% to 82%). 
As  we  expected,  total  BD-BAL  cell  numbers,  lymphocytes, 
macrophages  and  neutrophils,  were  increased  in  significant 
numbers in active BD (Table 2).
Detection of BAFF in BAL fluid. Figure 1 depicts the ELISA 
results for BAFF. BAFF level were less than the limit of detec-
tion in 4/15 BAL from BD patients. In the 11 other patients 
BAFF protein levels were significantly increased (median, 53.8 
pg/mL; range, 0–407.4 pg/mL) compared to values obtained 
in healthy controls (p = 0.001).
BAFF is known to circulate in the blood, and serum levels 
in active BD have been reported in the range of 190 to 440 pg/
mL.14 To elucidate whether an increase of BAFF protein levels 
in BAL fluid reflects local production in the airway or whether 
it reflects plasma leakage, we measured the concentration of 
albumin and used it as a marker of plasma exudation.
Albumin  concentrations  in  BAL  fluid  were  significantly 
increased in active BD (0.40 mg/mL; range, 0.08–2.96 mg/mL) 
compared to BAL from healthy controls (0.030 mg/mL; range, 
0.010–2.030 mg/mL). When we normalized the concentration 
of BAFF to the concentration of albumin in BAL fluid and 
serum, the BAFF concentration in BAL fluid of BD patients 
(314.49  ± 41 5 pg/mg albumin) was still significantly higher 
than in BAL fluid from healthy controls (37.71 ± 88.40 pg/mg 
albumin;  p  =  0.0096;  Fig.  1B).  BAL-BAFF  levels  normal-
ized  to  albumin  still  expressed  at  lower  levels  when  com-
pared with levels in sera (6101.3 + 1831.82 pg/mg albumin;   
p = 0.0001). These data suggested that BAFF is released in the 
airways.
Levels  of  BAFF  correlate  with  inflammatory  cells  and 
cytokines. In the BD-BAL fluid, BAFF levels were strongly 
correlated with absolute numbers of total cells (r = 0.823, p = 
0.001) (Fig. 2A), lymphocytes (r = 0.709, p = 0.001) (Fig. 2C), 
Table 1. Clinical features of patients with Behçet disease (BD) with 
pulmonary involvement
Lesions Number of patients (%)
Oral ulcer 15 (100%)
Genital ulcer 15 (100%)
Eye lesions 10 (66%)
Skin lesions 
(erythema nodosum, folliculitis, …)
8 (53.3%)
Arthritis 15 (100%)
Vascular symptoms 12 (80%)
Overall burden of the disease manifestations in BD patients is 
described. patients received colchicine, steroids/cyclosporine. The 
pulmonary arteries are the second most common site of arterial 
  involvement, preceded by the aorta. Aneurysms are more common 
than thrombosis.3124  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 2
This study provides the first demonstration that IL-13-levels 
were  significantly  increased  in  BD-BAL  fluid.  Contradictory 
results were reported in serum-IL-13 level in BD. Increased IL-13 
(Th2) level were reported in active BD,22 which contrasted with 
results from Raziuddin et al.23 We think that Th1/Th2 cytokines 
production is dependent of the inflammatory site. The presence 
of IL-13 in BAL from BD patient with pulmonary involvement 
could be partially explained by allergic inflammation considering 
the greater importance of IL-13 in the effector phase of allergic 
airway disease. The prevalence of Th2 cell-mediated diseases, 
such as atopic diseases, has been noted to be low in Th1-cell-
mediated diseases. Blood eosinophil count and serum total IgE 
levels were found low in BD patients compared to allergic bron-
chial asthma.24,28 However, high IgE levels were detected in cer-
tain patients with BD as in patients with bronchial hyperactivity.28 
BAFF in antigen-challenged airways. IL-6 and IL-13 were also 
produced locally and their concentrations were strongly cor-
related with concentrations of BAFF. Collectively, these data 
suggest that local production of the B-cell-stimulating cytok-
ines BAFF, IL-13 and IL-6 might play a role in local B-cell 
responses in the lower airways of patients with allergic inflam-
matory diseases.
Deregulated production of interleukin-6 (IL-6) has been 
found  in  several  inflammatory/autoimmune  disorders.19,20 
Increased IL-6 levels have been reported in sera21-23 and in 
peripheral blood mononuclear cells of BD patients.24 In a recent 
study, IL-6 level was found increased in another inflammatory 
site: the CNS.25 IL-6 in CSF from BD predicted the long-term 
outcome of the patients. Some studies have found a correla-
tion between serum IL-6 levels and disease activity.26,27
Table 2. Inflammatory cells in bronchoalveolar lavage (BAL) fluid from Behçet disease (BD)
Control subjects Behçet’s disease p value¤
Total cells (106 cells) 10.2 (9.4–21.6) 18.5 (10.9–42.0) 0.001
Macrophages (106 cells) 9.8 (7.5–22.8) 16.9 (10.52–42.5) 0.001
Lymphocytes (106 cells) 0.8 (0.4–5.8) 4.7 (1.9–22.8) 0.001
Neutrophils (106 cells) 0.9 (0.0–6.8) 2.6 (0.9–21.5) 0.001
Eosinophils (106 cells) 0.1 (0.0–1.2) 0.1 (0.0–1.5) 0.92
Values are presented as median (ranges). ¤significance Behçet disease versus control subjects. BAL samples from 15 BD patients with pulmonary 
involvements and 18 healthy controls were investigated. Aliquots of fluid were removed for measurement of cell counts with a hemocytometer, cell 
viability was determined by means of trypan blue dye exclusion. patients with BD exhibited increased values of total cell count in their BAL when 
  compared to healthy controls. significant differences were also observed Macrophages, lymphocytes and neutrophils were present in significant 
numbers in BAL from BD patients.
Figure 1. Increased B-cell-activating factor (BAFF) production in Bronchoalveolar lavage (BAL) fluid from active Behçet disease with pulmonary 
manifestations. hatched line indicates the limit detection. (A) Measurement of BAFF in BAL fluids obtained was performed by using eLIsA. The mean 
concentration of BAFF in active BD was increased (109.53 ± 21.78 pg/mL) when compared with BAFF values in healthy controls (4.83 ± 1.72 pg/mL). (B) 
BAFF concentration in BAL fluid was normalized to the concentration of albumin. BAFF concentration in BAL fluid of BD patients (314.49 ± 415 pg/mg 
albumin) was still significantly higher than in healthy controls (37.71 ± 88.40 pg/mg albumin; p = 0.0096); (B) suggesting that BAFF is produced locally 
in the lower airway of BD patients. These results do not totally eliminate the possibility that active transport contribute to the increased appearance of 
BAFF in BD-airways. Local production of BAFF might have either a protective or pathogenic role.www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  125
BD patients with pulmonary involvement were positively cor-
related  with  the  numbers  of  macrophages,  lymphocytes  and 
neutrophils but not eosinophils. This suggests that infiltrating 
macrophages, lymphocytes and neutrophils might play a greater 
role in BAFF production in the airways.
Recently, it has been reported that BAFF levels are increased 
in nasal polyp tissue from patients with chronic rhinosinusitis 
and  in  the  upper  airway  include  mucosal  epithelial  cells  and 
This  result  may  probably  reflect  nonspecific  inflammation   
which is seen in BD.28
We did not identify the origins of BAFF production in the 
lower airways. It is well known that BAFF is produced by mono-
cytes, macrophages, DCs, neutrophils and epithelial cells from 
several tissues, including lung. Several groups have reported that 
T and B lymphocytes are capable of producing BAFF.13,29,30 Our 
present study showed that BAFF concentrations in BAL fluid of 
Figure 2. (A) significant correlation of B-cell-activating factor (BAFF) with total (106 cells) inflammatory cells. Cell viability was determined by means 
of trypan blue dye exclusion, and differential cell counts were obtained by using a Diff-Quik stain (American scientific products, McGaw park, IL) 
of cytocentrifuge preparations (Cytospin; shandon southern Instruments, Inc., sewickley, pA). Correlations were assessed with the spearman rank 
correlation. significant correlation was observed between BAFF level and bronchoalveolar lavage total inflammatory (106) cells (r = 0.823, p = 0.001). 
The concentrations of BAFF detected in BAL fluid were highly correlated with the absolute numbers of recruited inflammatory cells. (B) significant 
correlation of B-cell-activating factor (BAFF) with bronchoalveolar lavage (BAL) macrophages (106 cells). Differential cell counts were obtained by using 
Diff-Quik staining of cytocentrifuge preparations. Correlations were assessed with the spearman rank correlation. significant correlation was observed 
between BAFF level and BAL macrophages (r = 0.742, p = 0.001). The concentrations of BAFF detected in BAL fluid were highly correlated with the ab-
solute numbers of macrophages. (C) significant correlation of B-cell-activating factor (BAFF) with bronchoalveolar lavage (BAL) lymphocytes (106 cells). 
Differential cell counts were obtained by using Diff-Quik staining of cytocentrifuge preparations. Correlations were assessed with the spearman rank 
correlation. significant correlation was observed between BAFF level and BAL lymphocytes (r = 0.709, p = 0.001). The concentrations of BAFF detected 
in BAL fluid were highly correlated with the absolute numbers of recruited inflammatory lymphocytes. (D) significant correlation of B-cell-activating 
factor (BAFF) with bronchoalveolar lavage (BAL) neutrophils (106 cells). Differential cell counts were obtained by using Diff-Quik staining of cytocen-
trifuge preparations. Correlations were assessed with the spearman rank correlation. significant correlation was observed between BAFF level and 
bronchoalveolar lavage fluid (BAL) neutrophils (r = 0.809, p = 0.001). The concentrations of BAFF detected in BAL fluid were highly correlated with the 
absolute numbers of recruited neutrophils.126  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 2
whose chest X-ray (CXR), bronchial examination, and pul-
monary functions were normal. None of them had evidence of 
acute infection or chronic disease (e.g., other autoimmune or 
atopic disorders). Informed consent was obtained from all of 
unidentified infiltrating cells in the lamina propria28 and in 
BAL  from  asthmatics.31  This  suggests  that  overproduction 
of BAFF contribute to the inflammation through expansion 
and activation of B-cells. This would support the suggestion 
that both infiltrating cells in BAL fluid and tissue epithelial 
cells might produce BAFF in the lower airways. In either case 
the correlation of local BAFF production with the influx of 
inflammatory cells suggests that BAFF production is an inte-
gral  part  of  the  inflammatory  response.10,32  Future  studies 
will be required to determine the precise nature of the BAFF-
producing cells in the lung from BD patients with pulmonary 
involvement.
In summary, we report here that BAFF is upregulated in the 
BAL from BD patients with pulmonary involvement. BAFF 
levels were highly correlated with levels of IL-13 and IL-6. 
Our findings indicate that BAFF and other B-cell-stimulating 
cytokines are produced locally in the BAL and might contrib-
ute to local B-lymphocyte responses in airway inflammatory 
BD and in host defense. These results suggest that BAFF and 
its signaling in B-cells contribute to B-cell abnormalities and 
the development of pulmonary manifestation in patients with 
BD. Production of BAFF in inflammatory sites might have 
either a protective or pathogenic role in immunity.
Methods
Patients.  We  studied  15  active  BD  patients  (14  males  and   
1 female; nonsmoking patients; mean age: 47.5 years; range: 
32–56 years). They were selected on the basis of the crite-
ria defined by the International Study Group for diagnosis of 
Behçet disease.1 Clinical features of the patients with active 
stage  are  given  in  Table  1,  which  describe  overall  burden 
of the disease manifestations in BD patients. All active BD 
patients have pulmonary manifestations. Active BD patients 
were always treated with steroids and colchicine. The control 
subjects consisted of 18 nonsmokers (16 men and 2 women; 
mean age: 45.4 years; range: 37–45 years) undergoing rou-
tine  investigations  for  suspected  bronchial  carcinoma  and 
Figure 3. (A) Measurement of B-cell activators interleukin (IL)-6 and 
IL-13 in bronchoalveolar lavage (BAL) from patients with Behçet disease 
(BD) with pulmonary manifestations. IL-6 and IL-13 levels were per-
formed with cytometric bead array (CBA) assay as reported in materials 
and methods. Increased levels of IL-6 and IL-13 were observed between 
BD patients and healthy controls (p = 0.0001). This result indicated 
an expanded production of inflammatory mediators in BAL from BD 
patients with pulmonary manifestation. Collectively, these data suggest 
that local production of the B cell-stimulating cytokines BAFF, IL-13 
and IL-6 might play a role in local B-cell responses, in the lower airways 
of patients with BD. (B) Correlations between B cell-activating factor 
(BAFF) (pg/ml) and interleukin (IL-6) levels in bronchoalveolar lavage 
(BAL) fluid. Correlation was assessed with the spearman rank correla-
tion. significant correlation was obtained between BAFF and IL-6 levels 
(r = 0.882; p < 0.001) in Behçet disease (BD). (C) Correlations between B 
cell-activating factor (BAFF) (pg/ml) and interleukin (IL-13) (pg/ml) levels 
in bronchoalveolar lavage (BAL) fluid. Correlation was assessed with 
the spearman rank correlation. significant correlation was obtained be-
tween BAFF and IL-13 levels (r = 0.659; p < 0.001) in Behçet disease (BD).www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  127
Laboratory, Montgomery, TX), IgA (Bethyl Laboratory), and 
sIgA (ALPCO Diagnostics, Salem, NH) in BAL fluids were mea-
sured with specific ELISA kits as we have recently reported.18,33 
The minimal detection limits for BAFF is 31 pg/mL.
The  concentrations  of  albumin  (Bethyl  Laboratory, 
Montgomery, Tex), IgA (Bethyl Laboratory), and sIgA (ALPCO 
Diagnostics, Salem, NH) in BAL fluids were measured with 
specific ELISA kits. The minimal detection limits for these kits 
are 6.25 ng/mL, 7.8 ng/mL and 22.2 ng/mL, respectively. The 
concentrations of IL-6, IL-17 and MMP-9 in BAL fluids were 
measured by using a cytometric bead array (CBA) human IL-6 
Flex Set. In brief, 50 µL of the mixed capture beads and 50 µL 
of BAL fluid were incubated for 1 hour at room temperature. 
After adding 50 µL of the phycoerythrin detection reagent to 
the mixture and incubation for 2 hours at room temperature, 
the beads were then washed with the wash buffer and analyzed 
with a BD FACSArray Bioanalyzer (BD Biosciences). The CBA 
data were analyzed with FCAP Array software version 1.0.1 (BD 
Biosciences). The minimal detection limits are 5 pg/mL(IL-6), 
5 pg/mL(IL-13) and 1 ng/mL(IgE).
Statistical analysis. All data are reported as medians (ranges, 
minimum  to  maximum).  Differences  between  groups  were 
analyzed by using the Wilcoxon signed-rank test or the Mann-
Whitney U test. Correlations were assessed by using Spearman 
rank correlation. A p value of less than 0.05 was considered 
significant.
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Bronchoalveolar  lavage.  Bronchoscopy  was  performed 
according  to  standard  guidelines,  as  described  previously.33 
Thirty minutes prior to the procedure patients received 0.5 mg of 
atropine and 12.5 mg codeine intramuscularly. Local anaesthe-
sia of the oropharynx was achieved by Novesine spray (Wander, 
Switzerland) until gag reflexes subsided. Bronchoscopy was per-
formed using a Pentax bronchoscope through which 150 ml of 
normal prewarmed saline in aliquots of 20 ml were instilled 
into a subsegment of the right middle lobe. BAL fluid was then 
immediately aspirated by gentle hand suction into plastic tubes 
and kept at 4°C on ice.
Processing of BAL cells. BAL samples were filtered through a 
two-layer sterile gauze into sterile plastic vials (Falcon, Oxnard, 
CA), centrifuged at 4°C and 500 g for 10 minutes. The super-
natant was removed and cells were washed twice in PBS. The 
total cell number was counted using a Neubauer hemocytom-
eter (Brand, Wertheim, Germany). Differential cell counts were 
performed after Giemsa staining (Merck, Darmstadt).
Cell counts. The volume of fluid recovered from each 100-mL 
lavage specimen was recorded. Before centrifugation, aliquots of 
fluid were removed for measurement of cell counts with a hemo-
cytometer, cell viability was determined by means of trypan blue 
dye exclusion, and differential cell counts were obtained by using a 
Diff-Quik stain (American Scientific Products, McGaw Park, IL) 
of cytocentrifuge preparations (Cytospin; Shandon Southern 
Instruments,  Inc.,  Sewickley,  PA),  as  previously  described.33 
Total cells were calculated as the volume of BAL fluid recovered 
multiplied by cells per milliliter by hemocytometer count. Total 
counts of each cell type were calculated as total cells multiplied 
by the percentage of each cell type determined by differential 
cell counts.
Soluble  protein  measurement.  The  concentrations  of 
BAFF (R&D Systems, Minneapolis, MN), albumin (Bethyl 
de la Technologie” of Tunisia (DGRST 
Staff).
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